By comparing the humoral/antibody and cellular responses of Pfizer-BioNTech’s Covid vaccine in immune-mediated inflammatory disease (IMID) patients and healthy subjects, an international research team led by scientists from New York University determined that anti-inflammatory methamine Pterin can reduce the effectiveness of vaccination.
Patients taking the drug Anti-inflammatory drugs electronic Immunomodulator methotrexate (Also known as purpterin) can develop immune response Not very strong after vaccination vaccine Against this Coronavirus SARS-CoV-2In other words, this popular drug is used to combat immune-mediated inflammatory diseases (IMID) Such as multiple sclerosis and rheumatoid arthritis-but there are also some forms Tumor -Will reduce the effectiveness of the vaccine Anti-coronavirusIn view of this risk, experts recommend that appropriate strategies be developed to maximize the immunization rate of patients receiving the above-mentioned medications.
To determine that methotrexate can significantly reduce the effectiveness of the Covid vaccine, an international research team led by American scientists at New York University (NYU) worked closely with colleagues at Friedrich-Alexander University. -Erlangen in Nuremberg (Germany).Researchers coordinated by Rebecca Haberman, a clinical professor in the Lange Health Medicine Department of American University, compared Body fluids/antibodies and cellular responses In two patient cohorts: the first consists of 51 patients, one of which Immune-mediated inflammatory disease Treatment at the Langone Institute and 26 healthy subjects Control group; The second is the other 31 German IMID patients and 182 healthy people.They both received two doses of Covid vaccine BNT162b2/Tozinameran (Business name community) Developed by an American pharmaceutical company Pfizer Cooperation with German biotech companies Biological Technology.
Through analysis to Protein S Oh spike The SARS-CoV-2 coronavirus in all participants after vaccination, Professor Haberman and colleagues observed, in healthy subjects and 37 receiving Biological medicine, Such as tumor necrosis factor inhibitors (Tumor necrosis factor); However, in the methotrexate group (45 subjects), only 62.2% of the subjects observed a good antibody response. The cellular immune response of patients receiving immunomodulatory drugs is also not so strong.On the one hand, in fact, healthy subjects and subjects who received anti-inflammatory drugs other than methotrexate developed into CD8 T cellsSpecifically to kill cells that have been infected with the coronavirus, people taking methotrexate did not show an increase in CD8 T cell activation after vaccination.
Although these are important results, the study authors stated that further investigation is needed to fully understand this issue. Even if the immune response is reduced, it does not mean that these patients are not protected. Coronavirus disease, Diseases caused by pandemic pathogens. Professor Haberman said in a report: “It is important to state that patients should not worry about our findings, because most patients with immune system diseases respond well to mRNA vaccines.” Press releaseShe added: “It is also possible that methotrexate may delay rather than prevent an adequate immune response against COVID-19.” “More research is needed to understand why there are so many patients with common immune diseases taking methotrexate. The ratio is flawed in terms of antibody and cell response,” said Jose U. Scher, a co-author of the study and a lecturer in the Department of Medicine. New York University Langone Campus. The expert added: “This may not necessarily mean that the vaccine is ineffective, but alternative strategies for vaccines must be studied.”
Strategies recommended by the authors of the study include suspending methotrexate during vaccination, reducing drug doses, and boosting anti-Covid vaccines. Research detailsMethotrexate blocks the immunogenicity of BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory diseases“Published in the professional scientific journal “Rheumatism Yearbook”.